Events & Presentations

Investors

Events & Presentations

Upcoming Events
Date Event Details Remind Me
May 23, 2019 8:30 AM EDT
20ᵀᴴ Annual B. Riley FBR Institutional Investor Conference
Christopher Anzalone, Ph.D., Arrowhead’s president and chief executive officer, will participate in a fireside chat presentation with Mayank Mamtani, B. Riley FBR research analyst
Beverly Hills
Archived Events
Date Event Details
Nov 7, 2018
International HBV Cure Workshop 2018
Toronto
November 7, 3:35 p.m. EST – Bruce Given, M.D., Arrowhead’s chief operating officer, will deliver an oral presentation titled, “Clinical update on reducing HBV virus and antigen production using RNAi”
Nov 6, 2018
BIT’s 16th Annual Congress of International Drug Discovery Science and Technology
Jinan, China
November 6, 11:20 a.m. CST – Zhen Li, Ph.D., Arrowhead’s senior vice president of chemistry and non-clinical development, will deliver a keynote presentation titled, “Discovery and Development of Arrowhead Clinical Candidates ARO-AAT and ARO-HBV”
Oct 18, 2018 11:15 AM MDT
North American Cystic Fibrosis Conference
Denver, CO
Erik Bush, Ph.D., Arrowhead’s director of extra-hepatic targeting, will deliver a poster presentation titled, “A novel targeted RNAi molecule (TRiM™) delivery platform for the therapeutic inhibition of ENaC in cystic fibrosis lung disease”
Oct 16, 2018 1:00 PM EDT
Arrowhead Analyst R&D Day 2018
New York, NY
Arrowhead management and external key opinion leaders will discuss Arrowhead’s emerging pipeline of RNAi therapeutics
Oct 9, 2018 1:00 PM EDT
Chardan 2nd Annual Genetic Medicines Conference
New York, NY
Bruce Given, M.D., Arrowhead’s chief operating officer, will participate in a fireside chat.
Oct 5, 2018 7:00 AM EDT
2018 International HBV Meeting - The Molecular Biology of Hepatitis B
Taormina, Italy
October 5, 1:00 p.m. CEST –Christine Wooddell, Ph.D., Arrowhead’s director of liver targeting, will deliver a poster presentation titled, “Gene expression analysis during and after RNAi treatment of chronically HBV infected chimpanzees”
Oct 4, 2018 8:30 AM EDT
Arrowhead/Janssen Collaboration Call
Oct 2, 2018 10:55 AM EDT
2018 Cantor Fitzgerald Global Healthcare Conference
New York, NY
Christopher Anzalone, Ph.D., Arrowhead’s president and chief executive officer, will deliver a corporate presentation
Sep 30 - Oct 3, 2018
The 14th Annual Meeting of the Oligonucleotide Therapeutics Society
Seattle, WA

October 1, 9:20 a.m. PDT – Zhen Li, Ph.D., Arrowhead’s senior vice president of chemistry and non-clinical development, will deliver an oral presentation titled, “Direct conjugation approaches in RNAi come of age – Successful delivery outside of hepatocytes”

October 1, 5:00 p.m. PDT – Rui Zhu, Ph.D., Arrowhead’s senior process chemist, will deliver a poster presentation titled, “Subcutaneous delivery of an effective RNA interference (RNAi) therapeutic candidate silencing angiopoietin-like protein 3 for treatment of hyperlipidemia”

October 3,4:00 p.m. PDT – James Hamilton M.D., MBA,Arrowhead’s vice president of clinical development, will deliver an invited, late-breaker oral presentation titled, “Clinical Development of RNAi Therapeutics for HBV and Alpha-1 Antitrypsin Deficiency”

Sep 25, 2018 12:00 PM EDT
Antivirals: Targeting HBV and Beyond
James Hamilton, M.D., Arrowhead’s vice president of clinical development, will deliver an oral presentation titled, “Using siRNA to target the HBV transcriptome”